Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo

This study has been completed.
Information provided by (Responsible Party):
Nurettin Özgür Doğan, Kocaeli University Identifier:
First received: June 25, 2013
Last updated: May 2, 2014
Last verified: May 2014

This study aims to investigate efficacy of two different intravenous drugs (dimenhydrinate and piracetam) in the symptomatic management of peripheral vertigo.

The patients will be randomized in two groups according to symptomatic treatment modalities: Dimenhydrinate (100 mg) and piracetam (2 g) will be given in 100 cc normal saline in 30 minutes. Each patient will be asked if her/his vertigo symptoms resolved or not, according to a numeric rating scale (0=no vertigo, 10=worst possible vertigo). The patient will be rate the intensity of symptoms in the following times:

  • Numeric rating scale (1 to 10): Admission
  • Numeric rating scale (1 to 10): After the study drug (No ambulation)*
  • Numeric rating scale (1 to 10): After the study drug (Ambulation)*

    • Ambulation refers to head movements or walking in the room, if applicable.

Condition Intervention Phase
Peripheral Vertigo
Drug: Administration of 100 mg dimenhydrinate intravenous
Drug: 2 g piracetam intravenous
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
Official Title: Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo: A Double Blind Randomized Clinical Trial

Resource links provided by NLM:

Further study details as provided by Kocaeli University:

Primary Outcome Measures:
  • Change in numeric rating scale [ Time Frame: Change from baseline in numeric rating scale at 30th minute ] [ Designated as safety issue: No ]

Enrollment: 94
Study Start Date: June 2013
Study Completion Date: May 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Piracetam
2 g intravenous piracetam
Drug: 2 g piracetam intravenous
Active Comparator: Dimenhydrinate
Dimenhydrinate 100 mg intravenous
Drug: Administration of 100 mg dimenhydrinate intravenous


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Presenting to emergency department with vertigo symptoms
  • Adult patients (over 18)
  • Agree to participate to study (understanding the study protocol and signing the informed consent form)

Exclusion Criteria:

  • Patients under 18 years
  • Patients diagnosed with ischemic/hemorrhagic stroke after neuroimaging
  • Patient diagnosed with transient ischemic attack
  • Pregnants
  • Patients taking any analgesics or antihistaminic drugs last 24 hours
  • Documented or declared allergy to dimenhydrinate, piracetam or benzodiazepines
  • Patients who do not agree to participate to the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01890538

Kocaeli University
Kocaeli, Turkey, 41000
Sponsors and Collaborators
Kocaeli University
Principal Investigator: Nurettin Özgür Doğan, M.D., Assistant Professor Kocaeli University
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Nurettin Özgür Doğan, Assistant Professor, Kocaeli University Identifier: NCT01890538     History of Changes
Other Study ID Numbers: KOU KAEK 2013/174 
Study First Received: June 25, 2013
Last Updated: May 2, 2014
Health Authority: Turkey: Ethics Committee

Keywords provided by Kocaeli University:

Additional relevant MeSH terms:
Ear Diseases
Labyrinth Diseases
Nervous System Diseases
Neurologic Manifestations
Otorhinolaryngologic Diseases
Sensation Disorders
Signs and Symptoms
Vestibular Diseases
Autonomic Agents
Gastrointestinal Agents
Histamine Agents
Histamine Antagonists
Histamine H1 Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs processed this record on May 30, 2016